Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Trials of HRS-1167 and SHR-4658
CompanyDrug

Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Trials of HRS-1167 and SHR-4658

AstraZeneca's Truqap Granted NMPA Approval for Breast Cancer Treatment
CompanyDrug

AstraZeneca’s Truqap Granted NMPA Approval for Breast Cancer Treatment

"Novo Nordisk's Sogroya Approved for Use in Boao Lecheng Medical Zone
CompanyDrug

Novo Nordisk’s Sogroya Approved for Use in Boao Lecheng Medical Zone

Regeneron's Eylea HD Receives FDA Priority Review for Macular Edema Treatment
CompanyDrug

Regeneron’s Eylea HD Receives FDA Priority Review for Macular Edema Treatment

BRL Medicine Secures IND Approval for BRL-301 CAR-T Therapy in R/R B-NHL
CompanyDrug

BRL Medicine Secures IND Approval for BRL-301 CAR-T Therapy in R/R B-NHL

Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment
CompanyDeals

Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment

Bayer Commissions Pennsylvania Facility Expansion After $44 Million Investment
Company

Bayer Commissions Pennsylvania Facility Expansion After $44 Million Investment

Takeda's Adzynma, BeiGene's Sonrotoclax, and Avistone's Andatinib Set for Priority Review in China
CompanyDrug

Takeda’s Adzynma, BeiGene’s Sonrotoclax, and Avistone’s Andatinib Set for Priority Review in China

Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102
CompanyDeals

Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102

Eli Lilly's Orforglipron Meets Primary Endpoint in Phase III ACHIEVE-1 Trial for Type 2 Diabetes
CompanyDrug

Eli Lilly’s Orforglipron Meets Primary Endpoint in Phase III ACHIEVE-1 Trial for Type 2 Diabetes

3SBio's 707 Bispecific Antibody Receives BTD for First-Line NSCLC in China
CompanyDrug

3SBio’s 707 Bispecific Antibody Receives BTD for First-Line NSCLC in China

NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development
CompanyDeals

NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development